Dissolved organic nutrients (C, N, P) in seawater on the continental shelf in the Southwestern South Atlantic with emphasis State Marine Park of Laje de Santos (SMPLS) - São Paulo - Brazil

O principal objetivo deste trabalho é avaliar distribuição sazonal e espacial do carbono orgânico dissolvido (COD), nitrogênio orgânico (NOD), fósforo orgânico dissolvido (POD) e ureia em 10 estações do Parque Estadual Marinho da Laje de Santos (PEMLS). As estações 1 a 4 (mais próximas do continente) e as estações de 5 a 10 (mais próximas do parque marinho), todas na plataforma continental. Os resultados mostram que não foram observadas variações sazonais estatisticamente significativas para o COD e POD, todavia, o COD e o NOD, no período de verão apresentaram um pequeno aumento mostrando o aumento da atividade biológica e a influencia continental. Por outro lado, o NOD apresentou valores elevados em junho (2014 - inverno) e janeiro de 2015, variando de 12.51 a 32.76 µmol L-1, segundo o método de análise ANOVA (p< 0,01). Foram observados baixos valores de NOD em janeiro de 2014 (0,32-8,98 µmol L-1), em um verão anormalmente seco, enquanto que os valores mais elevados foram observados em julho de 2014 (27.50 µmol L-1). Ureia apresentou valores baixos na região do PEMLS e zonas costeiras atingindo 4,00 µmol L-1. Muitas vezes, a concentração de ureia pode estar associada com atividade de mergulho no parque. COD, NOD e ureia apresentaram valores ou diferenças entre as estações no PEMLS (5-10) e aquelas mais costeiras (1-4). O COD nas estações costeiras atingiu 267 µmol L-1, enquanto que no PEMLS, o valor máximo foi de 100 µmol L-1. Nenhuma variação significativa foi observada quanto à distribuição espacial entre as estações costeiras e as do parque para o POD (ANOVA pThe main objective of this work is evaluate seasonal and spatial distribution of dissolved organic carbon (DOC), dissolved organic nitrogen (DON), dissolved organic phosphorus (DOP) and urea in 10 stations of the State Marine Park of Laje de Santos (SMPLS). Stations 1 to 4 (nearest the continent) and the stations 5 to 10 (nearest the marine park) all of them were on the continental shelf. The results show that no statistic significant seasonal variations were found for the DOC and DOP nevertheless DOC and DON in summer period were lightly above the winter period showing the increase in biological activities and continental influence. On the other hand, DON showed high values in June (2014 - winter) to January 2015, ranging from 12.51 to 32.76 µmol L-1 according to the ANOVA method (

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

OBJECTIVES The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials. METHODS Patients received 25 mg of rilpivirine once daily or 600 mg of efavirenz once daily, plus two nucleoside/nucleotide reverse transcriptase inhibitors. At screening, patients had alanine aminotransferase/aspartate aminotransferase levels ≤5× the upper limit of normal. HBV and HCV status was determined at baseline by HBV surface antigen, HCV antibody and HCV RNA testing. RESULTS HBV/HCV coinfection status was known for 670 patients in the rilpivirine group and 665 in the efavirenz group. At baseline, 49 rilpivirine and 63 efavirenz patients [112/1335 (8.4%)] were coinfected with either HBV [55/1357 (4.1%)] or HCV [57/1333 (4.3%)]. The safety analysis included all available data, including beyond week 48. Eight patients seroconverted during the study (rilpivirine: five; efavirenz: three). A higher proportion of patients achieved viral load <50 copies/mL (intent to treat, time to loss of virological response) in the subgroup without HBV/HCV coinfection (rilpivirine: 85.0%; efavirenz: 82.6%) than in the coinfected subgroup (rilpivirine: 73.5%; efavirenz: 79.4%) (rilpivirine, P = 0.04 and efavirenz, P = 0.49, Fisher's exact test). The incidence of hepatic adverse events (AEs) was low in both groups in the overall population (rilpivirine: 5.5% versus efavirenz: 6.6%) and was higher in HBV/HCV-coinfected patients than in those not coinfected (26.7% versus 4.1%, respectively). CONCLUSIONS Hepatic AEs were more common and response rates lower in HBV/HCV-coinfected patients treated with rilpivirine or efavirenz than in those who were not coinfected